Sinovac Biotech (SVA) Reports Q2 Loss of $0.17

Sinovac Biotech (NASDAQ: SVA) reported Q2 EPS of ($0.17), versus $0.04 reported last year. Revenue for the quarter came in at $1.38 billion, versus $18.49 billion reported last year.

For earnings history and earnings-related data on Sinovac Biotech (SVA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c